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transduced cells and therefore we hypothesize that the latent presence of CMV antigens in 
vivo will maintain the long-term presence of these T cells. These results demonstrate that 
redirection of virus specific T cells towards anti-leukemic reactivity can be an attractive 
strategy to use for clinical purposes. 
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Gene targeting is a powerful technique to introduce genetic change into the genome of 
eukaryotic cells. It is widely used to create defined mutations in murine embryonic stem 
cells and theoretically could be used to create or repair mutations in somatic cells. In this 
way gene targeting could be a powerful form of gene correction type gene therapy. Despite 
its potential, gene targeting has not been widely used in somatic cells because of its low 
efficiency. We report on a system based on the correction of a mutated GFP gene that allows 
the efficient study of gene targeting in somatic cells. Using this system we show that gene 
targeting is stimulated over 2000-fold by the introduction of a DNA double-stranded break 
in the target locus (DSB-GT). We find that the rate ofDSB-GTcan be increased by increasing 
the amount of repair substrate, the amount of homology between the gene target and repair 
substrate, and by increasing the frequency of double-stranded break creation. When we 
optimize conditions for DSB-GT we obtain targeting rates of 3-5%. Finally, we show that 
chimeric nucleases, protein fusions between zinc finger DNA binding domains and the 
endonuclease domain of the Fokl restriction enzyme, can stimulate gene targeting in the 
genome of human somatic cells by several-thousand fold. Our data provides a paradigm for 
the use of gene targeting as a form of gene therapy for monogenic diseases. 
Abstract# 822 
Direct Delivery of Adenoviral Vectors to Malignant Cells Using 
Tumor-Specific CTL. Patricia N. Yotnda, Nicolas Charlet-Berguerand*, 
Barbara Salvodo*, Clio M. Rooney*, Malcolm K. Brenner. Center for Cell 
and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. 
A major barrier to successful gene therapy of disseminated malignancy is our inability 
to generate targeted vectors that can cross multiple tissue boundaries to reach all tumor 
deposits. Specific cytotoxic T lymphocytes (CTL<), however, can be generated against 
tumor antigens, and in animal models and some human settings (Rooney et al Blood. 92: 1549-
55 l 998) these CTLs are able to cross tissue barriers and to specifically recognize tumor 
cells. We have attempted to combine the mobility and targeting functions ofT cells with the 
capacity of adenoviral vectors to efficiently transduce tumor cells and deliver oncolytic 
genes. As proof of principle, we genetically modified Epstein Barr Virus (EBV)specific-
CTLs (currently used for the treatment of EBY associated malignancies) to make them able 
to locally produce a therapeutic or lytic adenovirus when specifically activated by their 
target cells. The intent was to see whether these CTL would produce vector only on activation 
once they had encountered their tumor target, and to discover if the vector they produced 
would have functional activity. EBY specific CTLs were transduced with a Moloney based 
retrovirus encoding a CD40L promoter driving the El adenovirus gene. The CD40L 
promoter is strictly regulated by T cell activation and is functional only for a brief period 
during the T cell activation process. The CTL were also transduced by an El deficient 
chimeric Ad5F35 vector that we have previously shown is effective at transducing 
hemopoietic lineage cells that lack the conventional coxsackie adenovirus receptor (Yotnda 
et al, Hum Gene Ther.12:659-70 2001). We used Ad5/f35-GFP or Ad5/f35-TK to transduce 
the E l-CTLs (I 03 viral particles per cells). Twenty-four hours after transduction, 40% of the 
El-CTL expressed the Ad transgene. When these CTLs were co-cultured with A549 cells, 
which are highly sensitive to adenoviral transduction, less than 5% were transgene positive, 
indicating low baseline production of active adenovector by CTL "producer" cells. When 
autologous, but not allogeneic, EBY-infected B cells (EBV-LCL) were added to the cultures. 
>95% of A549 target indicator cells were transduced by day 4 of culture, indicating increased 
vector production following T cell activation. Of the autologous EBV-LCL in the culture, 
38% were transduced, even though these target cells are much more resistant than A549 
cells to adenoviral vector transduction. Vector production decreased over 2-3 days, falling 
to 5-10% of peak values by day 4, but could be increased upon restimulation of the CTLs 
by fresh autologous tumor cells (EBV-LCL). The virus production decreased to 5-10% 4 
days after the last stimulation. Directed delivery of adenoviral vectors to malignant cells 
using tumor-specific CTL may be a useful addition to cellular-based cancer immunotherapy. 
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Recombinant adeno-associated virus (rAAV)° vector is an attractive viral vector to treat 
genetic diseases. Although extrachromosomal vector genomes are the most predominant 
form of vector DNA, we and others have established that rAAV vector does integrate into 
host chromosomes of hepatocytes in vivo. Although the integration efficiency is normally 
very low even when very high doses are used (Nakai et al., J. Virol. 75: 6969-6976, 2001. 
and in press), rAAV vector integration has raised the concern of insertional mutagenesis 
since: l) development of hepatic tumors was reported in rAAV-treated 
mucopolysaccharidosis type VII mice (Donsante et al., Gene Ther. 17:1343-1346, 2001) 
and 2) frequent chromosomal deletions were observed at rAAV integration sites in in vitro 
cultured cells (Miller et al.. Nat. Genet. 30: 147-148. 2002). However, the alteration of host 
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chromosomal DNA as a result of vector integration in vivo is not known. As a first step 
toward elucidating the host chromosomal effects of integration in vivo, we attempted to 
isolate the whole rAAV proviral genomes together with flanking host chromosomal 
sequences using a hereditary tyrosinemia type I (HT!) mouse model with fumarylacetoacetate 
hydrolase (FAH) deficiency. In the absence of NTBC drug administration, these mice 
accumulate toxic tyrosine metabolites that result in a cell autonomous lethal phenotype. 
Thus. genetically corrected hepatocytes have a selective advantage and can repopulate the 
liver. We constructed an FAH-expressing rAAV shuttle vector whose vector sequences are 
then retrieved in bacteria. HT! mice were injected via the portal vein with 3x 10 11 particles 
of AAV-FAH, and in vivo selection (removal of NTBC) was started 6 weeks post-injection. 
Hepatocytes were isolated after an 8-week in vivo se1ectiun, transplanted into HTI mouse 
recipients ( l x l O' hepatocytes per mouse), selected again in vivo for 7 months, and then the 
livers were harvested for DNA extraction. The transplantation and second in vivo selection 
facilitated dilution of extrachromosomal genomes present in the liver samples. The whole 
proviral genomes were isolated from the liver samples together with adjoining cellular 
DNA with a standard plasmid rescue technique, and sequenced. To date, 12 proviral genomes 
were characterized and sequenced. The vector genomes were frequently deleted at both 
terminals and AAV-ITRs were completely deleted in some cases. rAAV integration commonly 
accompanied a host chromosomal DNA deletion (by 2, 4, 13, 21, 27, 44, 58, 119, 216, 274 
and 2107 base pairs). A small insertion of unknown origin of up to 4 bp at junctions was 
sometimes observed. There was no significant homology between vector and cellular DNA 
sequences, while there was some microhomology of up to 4 bp between them. Integration 
sites were randomly distributed in chromosomes (chr. #I, 2, 4, 8, 9, 11, 15, 19) and there 
appeared to be no hot spot for vector integration. Five out of 12 integrations targeted within 
predicted or known mouse genes. Because our study relied on in vivo selection and 
ultimately transgene expression, we cannot establish if these integration were representative 
of all r AAV integration events. However, for the purposes of gene therapy, elucidating the 
structures of proviral genomes and the sites where the expressible transgene inserts is an 
important parameter. This study is the first we are aware of that establishes the imperfect 
nature of rAAV vector integration in vivo. 
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Primary T cells expressing chimeric receptors specific for tumor antigens have 
considerable therapeutic potential. Their successful therapeutic use has been limited because 
most tumor cells lack the costimulatory molecules essential for the induction and maintenance 
of a T cell response. B cells latently infected with Epstein Barr virus (EBV-LCL) are known 
to be excellent antigen-presenting cells that are rich in costimulatory molecule expression. 
Cell surface expression ofCDl 9 is shared between EBV-LCLand many B cell malignancies, 
including B cell precursor acute lymphoblastic leukemia (ALL). To investigate the role of 
costimulation for chimeric receptor-mediated T cell functionality, we generated EBY-specific 
cytotoxic T lymphocytes (CTLJ from four healthy seropositive donors and transduced them 
with a retroviral vector encoding the CD 19-specific chimeric receptor CD l 9-zeta. We then 
compared their capacity to respond to CD19+ tumor cells and to EBY-transformed CDl 9+ 
B cells. While nontransduced CTL were EBY-specific and HLA-restricted, lysing 36-78% 
autologous EBV-LCL in the absence of significant cytotoxicity against mismatched EBY 
or tumor targets, CD l 9-transduced CTL lysed both autologous (29-74%) and mismatched 
allogeneic EBV-LCL (46-73%) as well as the CDl9+ Reh leukemia cell line (37-44%) and 
primary ALL blasts (30-47% ), but not CD! 9-negative K-562 tumor cells (0-19% ). Whereas 
lysis of mismatched LCL and Reh cells was not significantly inhibited by HLA class 1 and 
II antibodies, up to 58% (Reh) and 49% (LCL) inhibition of lysis was obtained by 
preincubation with anti-CD19 monoclonal antibody, confirming a chimeric receptor-
mediated, non-MHC-restricted mechanism of recognition. Incubation of a clonal population 
of CD l 9-transduced CTL with CD l 9+ tumor targets failed to elicit a proliferative response, 
as demonstrated by [3H]thymidine incorporation. However, following coincubation with 
CD19+ mismatched allogeneic LCL, [3H]thymidine uptake was 54-80% of that obtained 
by native receptor stimulation using autologous LCL. In contrast, the failure of tumor cells 
to induce T cell proliferation could not be overcome by CD28 costimulation provided by 
antibody crosslinking. Hence, CD! 9-zeta-expressing CTL could not be maintained in 
culture for longer than three weeks when stimulated with CD l 9+ tumor cells even in the 
presence of immobilized anti-CD28 antibody. By contrast, co-culture with irradiated 
mismatched allogeneic LCL promoted expansion not significantly different from that 
observed with autologous LCL. Thus, chimeric receptor-mediated T cell proliferation and 
expansion are significantly enhanced when the target antigen is expressed in the cellular 
microenvironment of a professional antigen-presenting cell. By delivering abundant and 
diverse costimulatory signals along with the chimeric receptor signal, adoptively transferred 
CD 19-zeta-expressing EBV-CfL may induce long-lasting immune control of B cell precursor 
leukemia. As the modified cells maintain their native specificity for EBY, this strategy may 
be exceptionally useful for patients recovering from allogeneic stem cell transplantation, 
thus preventing both EB V-associated lymphoproliferative disease and leukemia relapse. 
